PAR

1.92%

25.5¢ paradigm biopharmaceuticals limited..

As an Anaesthetist (and expert in pain management), the evidence...

First 16 Last

Share
Profile

Follow
cphil1970

17 Posts.

16

30/11/20

11:42

Post #: 49233544
Share
Originally posted by Mozzarc: ↑

Yes agreed, I think the jury is out, there are some trials that are taking place or being constructed, but a lot more needs to be done. There are a number of issues and while not exhaustive, some issues include the below. Certainly not comparable to the hard and clinical evidence we are witnessing with iPPS and it's respective safety profile and benefits to date:

Can be additive - "It has been shown that one in every eleven individuals (9% of individuals) consuming cannabis will become dependent on the drug". ¹

In terms of patients, it is usually dose dependant, it's not a set formula like how iPPS works. Thus each patient will have to have their dosage theoretically tailored for them. Results will vary, there are a number of factors that could make it more or less effective. (eg how much food, what you have consumed recently, how it mixes etc etc.

Longer term usage specifically for OA is not known, "Even though pain management is one of the most common reasons people use medical marijuana in the U.S., there is limited evidence that marijuana works to treat most types of chronic pain." ²

More research via clinical trials needs to be done

Some variants can have effects on the brain (make you high etc), there could be increased risk of schizophrenia or other psychotic illnesses, again longer term studies need to test this.

Route of administration, again more works need to be done, smoking it can have carcinogenic properties, finally there is an amount of ash you are breathing in.

Other issues involved, will be years before they can (if they are ever successful) in tailoring something in this area for OA, even then not sure it will line up to iPPS in any meaningful way.

Just to me, it sounds more along the lines of opioids and temporary pain management, then blanket pain suppression as opposed to the well, "Multi Modal" pathways as recently mentioned.

DYOR as usual

REFERENCES
1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053383/
2) https://www.cdc.gov/marijuana/health-effects.html

Expand

As an Anaesthetist (and expert in pain management), the evidence for the benefit of cannabis in pain relief in the scientific literature remains marginal at best. This is evidenced by our College of Anaesthetists/Faculty of Pain Medicine position statements...(can provide more info if needed)
certainly nothing near the benefit provided by PPS
PAR Price at posting: $2.99 Sentiment: Buy Disclosure: Held
20 Upvote

0 Great analysis

Reply

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

RCE

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

There are more pages in this discussion • 16 more messages in this thread...

First 16 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change -0.005(1.92%)		Mkt cap ! $89.19M

Open	High	Low	Value	Volume
27.0¢	27.0¢	25.5¢	$261.4K	990.7K

Buyers (Bids)

No.	Vol.	Price($)
1	9999	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	9445	1

View Market Depth

No.	Vol.	Price($)
1	9999	0.255
5	259000	0.250
4	96000	0.245
9	261374	0.240
5	71970	0.235

Price($)	Vol.	No.
0.260	9445	1
0.275	44000	2
0.280	35900	3
0.285	6729	2
0.290	60000	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

PAR (ASX) Chart

As an Anaesthetist (and expert in pain management), the evidence...

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

As an Anaesthetist (and expert in pain management), the evidence...

Top Stories

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News